Welcome to AlgiPharma

Print Send mail to friend Add to favorite
AlgiPharma AS is a biopharmaceutical company with primary focus on respiratory diseases, wound healing and other conditions caused by microbial infections and biofilms.

The company’s vision is to be a leading biopharmaceutical company in the field of disruptive alginate oligomer technologies with the aim to meet unmet medical needs and fight diseases effectively through innovative therapies.

AlgiPharma has successfully completed a phase 2a clinical trial in Cystic Fibrosis. The drug candidate has proven to be safe and well tolerated, and a phase 2b trial is being planned for 2014 / 2015. The AlgiPharma drug candidate for Cystic Fibrosis has Orphan Drug designation from the European Medicines Agency.

AlgiPharma’s anti-infective product candidates has shown efficacy in animal infection models and is currently being evaluated for human studies.
All rights reserved AlgiPharma. E-mail: yngvar.berg@algipharma.com | Created by : assist2net
Home | Company | Technology | Products | News |Contact us
W3C XHTML 1.0 W3C CSS Level 2
Home Søk Home Mail to us Search Sitemap Norwegian English